Mikhail Blagosklonny: Aggressively Innovative Approach to Cancer and Aging

Aging and cancer are foci whose solutions are yet to be exhaustively looked into. Many options have been considered so far, and viable options keep coming up especially with the advancement in technology. One of the hypotheses developed is the use of Rapamycin. This is also called Sirolimus or by the trade name, Rapumen. The drug was first formulated in 1972 from a bacterium found in Easter Island. In the beginning, the drug was used as an anti-fungal agent. That was abandoned as soon as it was suspected to have immunosuppressant and antiproliferative properties. Today, it is used to prevent negative response by the body after a transplant. Rapamycin is also common in cancer therapy. Dr. Mikhail Blagosklonny sparked interest in the subject of the role of Target of Rapamycin signaling in aging and cancer. By addressing cellular senescence associated with aging, the drug’s properties may be the find of the decade. Rapamycin was found to rejuvenate immunity. Rapamycin was also proposed in the treatment of Alzheimer’s and muscular dystrophy. Know more about Mikhail at Philly Purge.

Cancer Treatment despite Depth of Pocket

It is undeniable that cancer has become a global menace. Dr. Blagosklonny has conducted extensive research on the prevalence of malignant cells, particularly in advanced age. Many of his papers and lectures have revealed a lot of useful information on cancer, which will be relevant for years to come. The good doctors are on a mission to treat this life-threatening disease efficiently. Most importantly, they are seeking to device a way that is affordable and much less painful to the patient. Mikhail strives to find a way that can aid in eliminating cancerous cells without distorting the healthy cells. Cancer treatment is costly, and for a long time, it has been considered a reserve for the rich. Mikhail foresees a future where it is accessible by all people regardless of their social and financial eminence. Dr. Mikhail is hopeful that his research will be a stepping-stone to innovative cancer therapies in the future. It is Blagosklonny’s fervent hope that his students and next-generation scientists will continue his work. Read Mikhail’s plans for Oncology on Healingmagic.net.

Foundation of Passion

Mikhail Blagosklonny was a professor of Oncology at Roswell Park Cancer Institute in New York up until 2016. He got his MD in Internal Medicine from the First Pavlov State Medical University of St. Petersburg. Dr. Blagasklonny also holds a Ph.D. in Experimental Medicine and Cardiology from the same institution. He was an Associate Professor at New York Medical College in 2002. This was before he left to be a Senior Scientist at Ordway Research Institute until 2009. Dr. Mikhail Blagosklonny is the editor in chief of Aging, Cell Cycle, and Oncotarget.

Shift in Thinking

In a world where cancer and age-related illnesses are paralyzing global citizens, a more proactive startegy needs be taken to find new approaches to treatment and prevention. Dr. Mikhail Blagosklonny’s work has been instrumental in these fields. He is a deservedly revered professional with a legacy that will outlive him.

Learn more: https://classroomvoices.org/understanding-oncology-through-mikhail-blagosklonny/

Categories: Cancer Research

Oncotarget Publishes Findings Connecting Cell Rejuvenation To Proper Nutrition

A number of methods have emerged in an attempt to boost cellular rejuvenation and decrease the effects of aging. The most common one is based on nutrition; supported by dietary energy regulation. Based on a body of work published in Oncotarget, the significance of dieting and nutrition on extending lifespan and the deceleration of aging has grown immensely. Dietary energy regulation can be in the form of either calorie restriction or dietary restriction. In most cases, the two terms are used synonymously, but they bear ample differences.

Dietary restriction (DR) is achieved by simply decreasing the amount of food allocated per serving, while calorie restriction (CR) is accomplished by reducing the energy concentration by changing the composition of your diet. This means that CR requires more effort than DR, and this is why the use of DR is emphasized more for lifespan-lengthening activities. Using DR regimens are responsible for the deactivation of anabolic pathways for nutrients during fasting. Therefore, lifespan extension and cell rejuvenation processes are enhanced by the inhibition of mTOR functioning. Check the journal at SCImago Journal & Country Rank.

This is because mTOR activity invalidates rejuvenation because it limits the attainment of lifespan-lengthening effects brought about by DR. It also leads to aging and cellular degradation because of the repetitive distribution of nutrients caused by mTOR hyperactivity. Based on this, overeating or ad libitum feeding will lead to rapid aging. An energy-dense diet brings about accelerated aging, especially to those highly susceptible to diet-induced obesity. Because ad libitum feeding promotes obesity, a decrease in such patterns would lead to the unearthing of its hidden potential.

However, it has been discovered that cell rejuvenation based on DR methods will come at the expense of sexual reproduction and growth. The reason for this is that levels of major urinary proteins (MUPs) in the body decrease with the use of DR. This means that low MUPs levels lead to inhibited sexual growth.

About Oncotarget

It is a traditional free access journal that offers papers in Oncology, as well as other fields including, but not limited to Cell Biology, Anti-aging, Cardiology, and Neuroscience. The objective of Oncotarget is to avail scientific research findings promptly and ensure that authors increase the impression made by their research.

The current editors of Oncotarget are Mikhail Blagosklonny and Andrei V. Gudkov. The rights of works published online are retained by the authors, but through a Creative Commons Attribution License, other people can reuse, modify, distribute, and reprint articles. Visit Oncotarget’s profile page at facebook.com

Oncotarget is one of the leading online medical journals, with a 5-year impact factor of 5.415 by Scopus/SJR.

Categories: Cancer Research

How To Use Oncotarget To Become a Better Student

Oncotarget can be considered as being a primary source of learning for anybody. The website has been made to specifically enable people to take advantage of an opportunity in which they can share ideas by communicating with one another. Scholarly articles in the field of science are also uploaded weekly. It is important to note that although such elements of science are regularly updated on the website, a user should also work towards advancements in science in their spare time if they take the field of science quite seriously. Oncotarget is a website that allows people to use it as a way to support their very own works of advancements in science and is available on Impact Journals.

Not only is Oncotarget a viable option for advancing in science, it is also a wonderful site for one to improve their writing skills. One’s skills in writing can almost always use room for improvement. Although one may not necessarily be aware, there are many different elements of writing, many of which many writers do not necessarily even use, even the most proficient and prolific of them. By utilizing Oncotarget as much as possible, it’s highly recommended for you as a researcher and student to ensure that you’re taking necessary steps towards becoming a better writer, researcher, and observer simultaneously. All of these attributes in your learning can have effects of making you a better all around student. If you are unable to grasp certain elements of what is shown on the website, feel free to utilize the “Contact Us” page on the website as the representatives who are able to help may be able to provide you with some assistance that you may need to better understand what you may have concerns about. The aspect of the website in which it is updated weekly is something that makes the site worthwhile for anyone. View output styles at Endnote.com

Categories: Cancer Research

Mikhail Blagosklonny; a Scientist Determined to Fight Cancer and Aging by all means possible

Currently, Mikhail Blagosklonny is a professor of Oncology at Roswell Park Cancer Institute. Cancer has been seen to be the leading cause of death in all continents. This concept has attracted scientists from all walks of life to try and solve this problem by finding a cancer elusive treatment. As a scientist of Oncology, Mikhail Blagosklonny studies Cancer and Aging as he attempts to find a treatment for these two concepts. He has made numerous contributions towards finding an elusive treatment considering he is a specialist in treatment therapies and cancer biology. With his extensive research and academic background, Mikhail contributions in fighting cancer have some potential of being perfected to bring about cancer and aging treatment.

Career and Education Preview

Mr. Blagosklonny had the opportunity of studying at First Pavlov State Medical University based in St. Petersburg, Russia where he earned his MD in Internal Medicine and a Ph.D. in Cardiology and Experimental Medicine. With the help of his academic credentials, it was not hard for him to begin his career journey. In 2002, he joined the New York Medical College, Valhalla, New York as an associate professor. He later joined Ordway Research Institute as a research scientist. He continued to work in the firm as he wanted to gain the required experience. In 2009, he now joined Roswell Park Center to be a professor of Oncology a job he loves very much. He has been an excellent professor considering his experiences gained from working in different institutions. Some of his research interests include anti-aging and anticancer drugs, Biogerontology and therapies that protect healthy cells from being damaged.

Visit ResearchGate.Net to keep up to date with Mikhail’s latest work.

Research work

Mikhail Blagosklonny is responsible for authoring more than a hundred articles on the subjects of aging and cancer. He has also co-authored various research reviews and book chapters on both molecular and cellular biology of cancer cells considering their apoptosis, autophagy, and cycle. From his works cited he proposes the use of rapamycin, with the help of TOR signaling, to help in prolonging cell life in the human body. This is achieved through delaying autophagy, inhibiting apoptosis and promoting protein synthesis. He continues to argue that with the help of the TOR signaling regulation, cancer can be treated.

According to him, he believes it is possible to control aging and cancer, and he will one day be in a position of doing so. Check his LinkedIn profile to learn more.

Categories: Cancer Research